Thermo Fisher Scientific IL-27 p28 Monoclonal Antibody (MM27-7B1), Functional Grade, eBioscience

Applications

Tested Dilution

Publications

Flow Cytometry (Flow)

-

View 1 publication 1 publication

Neutralization (Neu)

Assay-Dependent

-

Functional Assay (Functional)

Assay-Dependent

-

Blocking Assay (BLOCK)

-

View 1 publication 1 publication

Product Specifications

Published species

Mouse

Host/Isotype

Mouse / IgG2a, kappa

Recommended Isotype Control

Mouse IgG2a kappa Isotype Control (eBM2a), Functional Grade, eBioscience™

Class

Monoclonal

Type

Antibody

Clone

MM27-7B1

Conjugate

Functional Grade Functional Grade Functional Grade

View additional formats

• PE
• Request custom conjugation

Form

Liquid

Concentration

1 mg/mL

Storage conditions

4° C

Shipping conditions

Wet ice

RRID

AB_2866268

Product Specific Information

Description: This MM27-7B1 monoclonal antibody reacts with the p28 subunit of Interleukin-27 (IL-27) and neutralizes the bioactivity of IL-27, a member of the IL-12 family. IL-27 is a heterodimer of the subunits EBI3 (Epstein-Barr Virus Induced Gene 3), which is homologous to the p40 subunit shared by IL-12 and IL-23, and p28 (IL-30), which is homologous to p35. It is produced by activated dendritic cells and macrophages in response to TLR ligands and inflammatory cytokines.

The IL-27 receptor shares one subunit, gp130, with other members of the IL-6 family. The subunit WSX-1 (IL-27R alpha, TCCR) is unique to IL-27 and is believed to be the only part of the receptor that interacts with the cytokine. The IL-27R is most abundantly expressed on activated T-cells and NK cells, although expression has also been shown on B-cells and naive T-cells. IL-27R activation leads to the phosphorylation of Jak/STAT proteins, with STAT1 and STAT3 being critical to the function of IL-27. IL-27 has been shown to have both pro-inflammatory and anti-inflammatory effects. It influences the commitment of CD4+ T-cells toward the Th1 lineage by inducing the expression of the T-bet transcription factor and the upregulation of IL-12R beta2. Its anti-inflammatory functions include the suppression of Th2 and Th17 proliferation and differentiation. Susceptibility to T-cell mediated autoimmunity has been observed in WSX-1 knockout mice.

Recent evidence suggests that the p28 subunit may also be secreted independently of EBI3 and have functions distinct to the IL-27 heterodimer. It is believed to not only antagonize the activity of IL-27, but also inhibit signaling of other gp130 ligands, such as IL-6 and IL-11.

Applications Reported: This MM27-7B1 monoclonal antibody inhibits the activity of mouse and human IL-27.

Applications Tested: The ND50 of MM27-7B1, as measured by the inhibition of protection agains EMC virus in HepG2 cells, is less than or equal to 120 ng/mL in the presence of 25 ng/mL of Mouse IL-27 Recombinant Protein. Neutralization dose will vary depending on assay method, cytokine concentration, and cell type. This antibody should be carefully titrated for optimal performance in the assay of interest.

Bioactivity: The ND50 of MM27-7B1, as measured by the inhibition of protection agains EMC virus in HepG2 cells, is less than or equal to 120 ng/mL in the presence of 25 ng/mL of Mouse IL-27 Recombinant Protein.

Storage and handling: Use in a sterile environment.

Filtration: 0.2 µm post-manufacturing filtered.

Purity: Greater than 90%, as determined by SDS-PAGE.

Endotoxin Level: Less than 0.001 ng/µg antibody, as determined by LAL assay.

Aggregation: Less than 10%, as determined by HPLC.

Target Information

IL-27, a member of the IL-12 family, is a heterodimeric protein consisting of the p40-related protein Epstein-Barr virus-induced gene 3 (EBI3) non-covalently linked to an IL-12p35-related protein, p28 (also known as IL-30). IL-27 is produced by activated APCs and mature dendritic cells. IL-27 exerts its activities on NK cells and naive CD4+ T cells; mRNA expression analysis of IL-27 receptor components (WSX-1/TCCR and gp130) suggests that IL-27 may also target other cells, including mast cells and monocytes. Binding of IL-27 to WSX-1/gp130 activates JAK1, STAT1, and STAT3 and STAT1/3 phosphorylation. WSX-1/TCCR-deficient mice develop impaired Th1 responses and are more susceptible to infection with L. monocytogenes suggesting that Th1 responses require IL-27. Although activation of WSX-1 is required for the initiation of Th1 responses, it is not necessary for maintaining Th1 responses. IL-27 alone is not able to induce the differentiation of CD4+ T cells into IFN-γ-producing cells, suggesting a role for IL-27 as an initial activator of Th1 responses. An important effect of IL-27 in initiating Th1 responses is the induction of the Th1-specific transcription factor T-bet as well as the suppression of the Th2-specific transcription factor GATA-3. T-bet plays a critical role in Th1 differentiation by its ability to maintain IL-12Rβ2 expression following CD4+ T cell activation. Recent studies indicate that IL-27 has a potent antitumor activity. In vitro, IL-27 has been found to act directly on naive CD8 cells, generating CTL with enhanced granzyme B expression. In vivo, IL-27 has been reported to augment CTL activity, inhibit tumor growth, and induce complete regression of primary and metastatic neuroblastoma tumors.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.